Inotiv, Inc. (NASDAQ:NOTV) CEO Sells $281,216.94 in Stock

Inotiv, Inc. (NASDAQ:NOTV) CEO Robert Jr. Leasure sold 73,617 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $3.82, for a total transaction of $281,216.94. Following the transaction, the chief executive officer now owns 956,592 shares in the company, valued at approximately $3,654,181.44. This represents a 7.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Robert Jr. Leasure also recently made the following trade(s):

• On Friday, January 31st, Robert Jr. Leasure sold 22,700 shares of Inotiv stock. The shares were sold at an average price of $4.15, for a total transaction of $94,205.00.

Inotiv Stock Up 9.0 %

Shares of Inotiv stock traded up $0.35 on Thursday, hitting $4.25. 882,402 shares of the company traded hands, compared to its average volume of 695,682. The company has a 50-day moving average price of $4.37 and a 200 day moving average price of $2.93. The company has a quick ratio of 1.28, a current ratio of 1.57 and a debt-to-equity ratio of 2.31. Inotiv, Inc. has a 12-month low of $1.23 and a 12-month high of $11.42. The company has a market cap of $143.31 million, a PE ratio of -0.92 and a beta of 3.58.

Inotiv (NASDAQ:NOTV) last issued its quarterly earnings data on Wednesday, February 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). Inotiv had a negative return on equity of 15.41% and a negative net margin of 25.40%. Sell-side analysts predict that Inotiv, Inc. will post -0.79 earnings per share for the current year.

Institutional Investors Weigh In On Inotiv

A number of large investors have recently bought and sold shares of NOTV. Balyasny Asset Management L.P. boosted its holdings in Inotiv by 7,714.8% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,303,741 shares of the company’s stock worth $5,397,000 after purchasing an additional 1,287,058 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in Inotiv during the 4th quarter worth $5,250,000. Vantage Point Financial LLC acquired a new position in Inotiv during the 4th quarter worth $1,393,000. Millennium Management LLC lifted its position in Inotiv by 553.7% during the 4th quarter. Millennium Management LLC now owns 287,899 shares of the company’s stock worth $1,192,000 after acquiring an additional 243,860 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Inotiv during the 4th quarter worth $737,000. 18.17% of the stock is currently owned by institutional investors.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.